In lupus, B cells release “autoantibodies” that latch onto the body’s cells, triggering a damaging immune response.
The therapy will now be tested in larger trials.
Five patients with hard-to-treat lupus entered remission after scientists tweaked their immune cells using a technique normally used to treat cancer. After the one-time therapy, all five patients with the autoimmune disease stopped their standard treatments and haven’t had a relapse.
This treatment, known as chimeric antigen receptor (CAR) T-cell therapy, needs to be tested in larger groups of lupus patients before it can be approved for widespread use. But if the results hold up in larger trials, the therapy could someday offer relief to people with moderate to severe lupus.
“For them, this is really a breakthrough,” said Dr. Georg Schett, director of rheumatology and immunology at Friedrich Alexander University Erlangen-Nuremberg in Germany. Schett is the senior author of a new report describing the small trial, which was published Thursday (Sept. 15) in the journal Nature Medicine.
“It’s a single shot of CAR T cells and patients stop all treatments,” Schett told Live Science. “We were really surprised [at] how good this effect is.”
Continue reading… “In a 1st, scientists use designer immune cells to send an autoimmune disease into remission”
